ArticlePharmaceutics2013
Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators.
Article in Pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 57 citations in OpenAlex.
- Emerging Trends in Lipid-Based Vaccine Delivery: A Special Focus on Developmental Strategies, Fabrication Methods, and Applications.Vaccines · 2023Review
- Preclinical developments in the delivery of protein antigens for vaccination.Expert opinion on drug delivery · 2023Article
- Article
- Nano/microparticle Formulations for Universal Influenza Vaccines.The AAPS journal · 2022Review
- Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity.Advanced healthcare materials · 2021Article
- Cationic Nanoparticle-Based Cancer Vaccines.Pharmaceutics · 2021Review
- Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.Molecular pharmaceutics · 2021Review
- Therapeutic Vaccination with Cationic Liposomes Formulated with Dioctadecyldimethylammonium and Trehalose Dibehenate (CAF01) and Peptide P10 Is Protective in Mice Infected withJournal of fungi (Basel, Switzerland) · 2020Article
- Mucosal Vaccination for Influenza Protection Enhanced by Catalytic Immune-Adjuvant.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Adjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccine.Turkish journal of biology = Turk biyoloji dergisi · 2020Article
- Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement.Influenza and other respiratory viruses · 2020Review
- Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization.Journal of controlled release : official journal of the Controlled Release Society · 2019Review
- Systems Immunology Characterization of Novel Vaccine Formulations forFrontiers in immunology · 2019Article
- Engineering a Next-Generation Glycoconjugate-Like Streptococcus pneumoniae Vaccine.ACS infectious diseases · 2018Article
- The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Frontiers in immunology · 2018Review
- Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates.NPJ vaccines · 2018Article
- Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.Frontiers in immunology · 2018Article
- Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Frontiers in immunology · 2018Review
- Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.Journal of nanobiotechnology · 2017Review
- Platform technologies for modern vaccine manufacturing.Vaccine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cationic liposomes are potential adjuvants for influenza vaccines. In a previous study we reported that among a panel of cationic liposomes loaded with influenza hemagglutinin (HA), DC-Chol:DPPC (1:1 molar ratio) liposomes induced the strongest immune response. However, it is not clear whether the cholesterol (Chol) backbone or the tertiary amine head group of DC-Chol was responsible for this. Therefore, in the present work we studied the influence of Chol in the lipid bilayer of cationic liposomes. Moreover, we investigated the effect of the HA loading method (adsorption versus encapsulation) and the encapsulation of immune modulators in DC-Chol liposomes on the immunogenicity of HA. Liposomes consisting of a neutral lipid (DPPC or Chol) and a cationic compound (DC-Chol, DDA, or eDPPC) were produced by film hydration-extrusion with/without an encapsulated immune modulator (CpG or imiquimod). The liposomes generally showed comparable size distribution, zeta potential and HA loading. In vitro studies with monocyte-derived human dendritic cells and immunization studies in C57Bl/6 mice showed that: (1) liposome-adsorbed HA is more immunogenic than encapsulated HA; (2) the incorporation of Chol in the bilayer of cationic liposomes enhances their adjuvant effect; and (3) CpG loaded liposomes are more efficient at enhancing HA-specific humoral responses than plain liposomes or Alhydrogel.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.